Skip to main content

Table 4 Worst pain experienced after electroporation (Study 1) as measured by the McGill Pain Questionnaire (0-5) a

From: Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors

  V930 DNA-EP V930 DNA-EP Total
  0.25 mg 2.5 mg  
  n (%) n (%) n (%)
Total number of patients 6 22 28
Worst pain experienced by patient:    
entire study b 1 (17) 3 (14) 4 (14)
 0 2 (33) 4 (18) 6 (21)
 1 2 (33) 6 (27 8 (29)
 2 1 (17) 5 (23) 6 (21)
 3 0 2 (9) 2 (7)
 4 0 2 (9) 2 (7)
 5    
Worst pain experienced by patient: day 1 b    
 0 1 (17) 6 (27) 7 (25)
 1 3 (50) 5 (23) 8 (29)
 2 2 (33) 5 (23) 7 (25)
 3 0 4 (18) 4 (14)
 4 0 1 (5) 1 (4)
 5 0 1 (5) 1 (4)
Worst pain experienced by patient: day 15 b    
 0 3 (50) 4 (18) 7 (25)
 1 3 (50) 6 (27) 9 (32)
 2 0 6 (27) 6 (21)
 3 0 3 (14) 3 (11)
 4 0 2 (9) 2 (7)
 5 0 1 (5) 1 (4)
Worst pain experienced by patient: day 29 b    
 0 3 (50) 5 (23) 8 (29)
 1 1 (17) 5 (23) 6 (21)
 2 1 (17) 7 (32) 8 (29)
 3 1 (17) 2 (9) 3 (11)
 4 0 1 (5) 1 (4)
 5 0 2 (9) 2 (7)
Worst pain experienced by patient: day 43 b    
 0 2 (33) 4 (18) 6 (21)
 1 2 (33) 8 (36) 10 (36)
 2 2 (33) 5 (23) 7 (25)
 3 0 2 (9) 2 (7)
 4 0 1 (5) 1 (4)
 5 0 2 (9) 2 (7)
Worst pain experienced by patient: day 57 b    
 0 2 (33) 5 (23) 7 (25)
 1 2 (33) 8 (36) 10 (36)
 2 1 (17) 2 (9) 3 (11)
 3 1 (17) 3 (14) 4 (14)
 4 0 1 (5) 1 (4)
 5 0 2 (9) 2 (7)
  1. aThe McGill Pain Questionnaire measured pain on a 6-point scale: 0 = no pain, 1 = mild, 2 = discomforting, 3 = distressing, 4 = horrible, and 5 = excruciating.
  2. bAs ranked by the patient.